AAFA Praises U.S. House Passage of the FASTER Act
November 17, 2020 21:34 ET | Asthma and Allergy Foundation of America
Washington D.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Today the House of Representatives passed H.R. 2117. Named the Food Allergy Safety, Treatment, and Research Act, it is easier known as the FASTER...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
October 20, 2020 10:00 ET | Intrommune Therapeutics
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal,...
Intrommune Logo Only - 250k.jpg
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
October 08, 2020 09:50 ET | Intrommune Therapeutics
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies. The article,...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Featured at Upcoming Investor Conferences
October 05, 2020 14:55 ET | Intrommune Therapeutics
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Intrommune Logo Only - 250k.jpg
Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal
September 01, 2020 15:55 ET | Intrommune Therapeutics
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
Asthma and Allergy Foundation of America (AAFA) Appoints Melanie Carver Chief Mission Officer
August 06, 2020 08:53 ET | Asthma and Allergy Foundation of America
Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the...
Intrommune Logo Only - 250k.jpg
Survey Confirms Physician Interest in Peanut Allergy Immunotherapy
February 03, 2020 09:04 ET | Intrommune Therapeutics
New York, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and other...
Intrommune Logo Only - 250k.jpg
Intrommune Participates in 2019 Food Allergy Fund Summit
November 26, 2019 15:41 ET | Intrommune Therapeutics
New York, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment for peanut and other food allergies delivered...
Intrommune Logo Only - 250k.jpg
POISED Study Supports Risk of Cessation of Oral Immunotherapy for Peanut Allergy; PACE Study Indicates Safer Peanut Allergy Treatment Approaches are Needed
November 07, 2019 10:00 ET | Intrommune Therapeutics
New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
September 16, 2019 14:25 ET | Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...